Amylyx Pharmaceuticals Inc
AMLX12.680USD
+0.500+4.11%
Handelsschluss 11/11, 16:00（ET）Kurse um 15 Minuten verzögert
1.39BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Amylyx Pharmaceuticals Inc Unternehmen
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate: AMX0035 for the treatment of Wolfram syndrome and for the treatment of progressive supranuclear palsy, and AMX0114, the Company’s antisense oligonucleotide targeting calpain-2 for the treatment of amyotrophic lateral sclerosis (ALS). AMX0035 is a dual-unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). The Company’s Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI), two indications characterized by hyperinsulinemic hypoglycemia.
Amylyx Pharmaceuticals Inc Informationen
BörsenkürzelAMLX
Name des UnternehmensAmylyx Pharmaceuticals Inc
IPO-datumJan 07, 2022
CEOMr. Justin Klee
Anzahl der mitarbeiter123
WertpapierartOrdinary Share
GeschäftsjahresendeJan 07
Addresse43 Thorndike Street
StadtCAMBRIDGE
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl02141
Telefon16176820917
Websitehttps://www.amylyx.com/
BörsenkürzelAMLX
IPO-datumJan 07, 2022
CEOMr. Justin Klee
Führungskräfte von Amylyx Pharmaceuticals Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Camille L. Bedrosian, M.D.
Dr. Camille L. Bedrosian, M.D.
Chief Medical Officer
Chief Medical Officer
182.34K
-6.19%
Dr. Bernhardt (Bernie) Zeiher, M.D.
Dr. Bernhardt (Bernie) Zeiher, M.D.
Independent Director
Independent Director
--
--
Dr. George Mclean Milne, Ph.D.
Dr. George Mclean Milne, Ph.D.
Chair of the Board of Directors
Chair of the Board of Directors
--
--
Ms. Lindsey Allen
Ms. Lindsey Allen
IR Contact Officer
IR Contact Officer
--
--
Mr. Joshua B. Cohen
Mr. Joshua B. Cohen
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
Mr. Paul Fonteyne
Mr. Paul Fonteyne
Independent Director
Independent Director
--
--
Mr. James M. Frates
Mr. James M. Frates
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Karen M. Firestone
Ms. Karen M. Firestone
Independent Director
Independent Director
--
--
Ms. Daphne E. Quimi, CPA
Ms. Daphne E. Quimi, CPA
Independent Director
Independent Director
--
--
Mr. Justin Klee
Mr. Justin Klee
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Camille L. Bedrosian, M.D.
Dr. Camille L. Bedrosian, M.D.
Chief Medical Officer
Chief Medical Officer
182.34K
-6.19%
Dr. Bernhardt (Bernie) Zeiher, M.D.
Dr. Bernhardt (Bernie) Zeiher, M.D.
Independent Director
Independent Director
--
--
Dr. George Mclean Milne, Ph.D.
Dr. George Mclean Milne, Ph.D.
Chair of the Board of Directors
Chair of the Board of Directors
--
--
Ms. Lindsey Allen
Ms. Lindsey Allen
IR Contact Officer
IR Contact Officer
--
--
Mr. Joshua B. Cohen
Mr. Joshua B. Cohen
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
Mr. Paul Fonteyne
Mr. Paul Fonteyne
Independent Director
Independent Director
--
--
Umsatzaufteilung
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Tue, Aug 19
Aktualisiert: Tue, Aug 19
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
10.36%
Adage Capital Management, L.P.
8.01%
Perceptive Advisors LLC
7.20%
TCG Crossover Management, LLC
5.41%
The Vanguard Group, Inc.
4.80%
Andere
64.21%
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
10.36%
Adage Capital Management, L.P.
8.01%
Perceptive Advisors LLC
7.20%
TCG Crossover Management, LLC
5.41%
The Vanguard Group, Inc.
4.80%
Andere
64.21%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
33.89%
Hedge Fund
32.13%
Investment Advisor/Hedge Fund
8.43%
Private Equity
7.77%
Individual Investor
7.46%
Venture Capital
2.25%
Research Firm
1.22%
Bank and Trust
0.07%
Pension Fund
0.05%
Andere
6.72%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
400
93.96M
85.66%
-8.75M
2025Q2
402
88.66M
100.38%
-5.79M
2025Q1
421
95.29M
107.20%
-3.35M
2024Q4
427
70.75M
84.73%
-29.75M
2024Q3
419
63.91M
89.33%
-37.09M
2024Q2
415
63.87M
89.96%
-35.05M
2024Q1
393
69.90M
101.03%
-23.62M
2023Q4
373
76.45M
112.48%
-12.85M
2023Q3
341
74.63M
110.02%
-3.94M
2023Q2
310
76.31M
113.70%
-2.01M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Fidelity Management & Research Company LLC
11.38M
10.67%
+8.33M
+273.33%
Sep 30, 2025
Adage Capital Management, L.P.
8.80M
8.25%
+3.10M
+54.45%
Jun 30, 2025
Perceptive Advisors LLC
7.90M
7.41%
+28.02K
+0.36%
Jun 30, 2025
TCG Crossover Management, LLC
5.94M
5.57%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
4.50M
4.22%
+381.52K
+9.27%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.85M
4.55%
+2.79M
+135.51%
Jun 30, 2025
Point72 Asset Management, L.P.
4.54M
4.25%
+3.62M
+394.70%
Jun 30, 2025
Klee (Justin B)
3.33M
3.12%
-29.98K
-0.89%
Sep 30, 2025
Cohen (Joshua Barry)
3.33M
3.12%
-29.93K
-0.89%
Sep 30, 2025
Saturn V Capital Management LP
3.26M
3.06%
+834.13K
+34.38%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Thu, Nov 6
Aktualisiert: Thu, Nov 6
Name
Anteil
SPDR S&P Pharmaceuticals ETF
1.34%
Invesco Dorsey Wright SmallCap Momentum ETF
1.13%
Invesco Dorsey Wright Healthcare Momentum ETF
1.09%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.01%
Federated Hermes MDT Small Cap Core ETF
0.46%
iShares U.S. Pharmaceuticals ETF
0.41%
iShares Micro-Cap ETF
0.18%
Vanguard US Momentum Factor ETF
0.15%
Fidelity Fundamental Small-Mid Cap ETF
0.13%
ProShares Ultra Nasdaq Biotechnology
0.13%
Mehr Anzeigen
SPDR S&P Pharmaceuticals ETF
Anteil1.34%
Invesco Dorsey Wright SmallCap Momentum ETF
Anteil1.13%
Invesco Dorsey Wright Healthcare Momentum ETF
Anteil1.09%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Anteil1.01%
Federated Hermes MDT Small Cap Core ETF
Anteil0.46%
iShares U.S. Pharmaceuticals ETF
Anteil0.41%
iShares Micro-Cap ETF
Anteil0.18%
Vanguard US Momentum Factor ETF
Anteil0.15%
Fidelity Fundamental Small-Mid Cap ETF
Anteil0.13%
ProShares Ultra Nasdaq Biotechnology
Anteil0.13%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
